We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
DEXMEDETOMIDINE INTAS, DEXMEDETOMIDINE ACCORD (Accord Healthcare Pty Ltd)
Product name
DEXMEDETOMIDINE INTAS, DEXMEDETOMIDINE ACCORD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 working days (255)
Active ingredients
dexmedetomidine
Registration type
New generic medicine
Indication
ICU Sedation
DEXMEDETOMIDINE INTAS, DEXMEDETOMIDINE ACCORD (solution for injection) are indicated for sedation of initially intubated patients during treatment in an intensive care setting. The use of DEXMEDETOMIDINE INTAS, DEXMEDETOMIDINE ACCORD by continuous infusion in these patients should not exceed 24 hours.
Procedural Sedation
DEXMEDETOMIDINE INTAS, DEXMEDETOMIDINE ACCORD are indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.